Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review

Hum Vaccin Immunother. 2022 Nov 30;18(5):2045857. doi: 10.1080/21645515.2022.2045857. Epub 2022 Mar 3.

Abstract

The U.S. Centers for Disease Control and Prevention (CDC) and other health agencies have recently recommended a booster dose of COVID-19 vaccines for specific vulnerable groups including adults 65 years and older. There is limited evidence whether vaccine effectiveness (VE) in older adults decreases over time, especially against severe COVID-19. We performed a rapid review of published studies available through 4 November 2021 that provide effectiveness data on messenger RNA (mRNA) vaccines approved/licensed in the United States and identified eight eligible studies which evaluated VE in older adults. There is evidence of a decline in VE against both severe acute respiratory syndrome coronavirus 2 infection and severe COVID-19 in older adults among studies which analyzed data up to July-October 2021. Our findings suggest that VE diminishes in older adults, which supports the current recommendation for a booster dose in this population.

Keywords: COVID-19; Vaccine; effectiveness; older adults; waning.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • COVID-19 Vaccines*
  • COVID-19* / prevention & control
  • Humans
  • RNA, Messenger
  • SARS-CoV-2 / genetics
  • United States
  • Vaccines, Synthetic
  • mRNA Vaccines

Substances

  • COVID-19 Vaccines
  • RNA, Messenger
  • Vaccines, Synthetic
  • mRNA Vaccines